»Ê¼Ò»ªÈË

XClose

Centre for Amyloidosis and Acute Phase Proteins

Home
Menu

National Amyloidosis Centre

Information for patients on the coronavirus (COVID-19)


±«±Ê¶Ù´¡°Õ·¡:Ìý As of 01 June 2020 the Centre for Amyloidosis has reopened. We will be conducting clinics via telephone/video-link, or where appropriate, in person. We will be in touch to let you know what type of appointment you will be having.

For FEVER PATIENTS who receive treatments at the Centre, such as Canakinumab, Anakinra and Tocilizumab, they will continue to have their appointments at this time.Ìý Please contact Michael Wood or Bella Sombrito if you have any questions.

Please follow this link for information on the coronavirus (COVID-19)
Ìý

Ìý

Head, UCL Centre for Amyloidosis and NAC Research Lead

Professor Julian Gillmore020 7433 2737/2798
NAC Clinical LeadProfessor Helen Lachmann020 7433 2737/2798
ÌýÌýÌý
Deputy Clinical and Research LeadProfessor Marianna Fontana020 7433 2764
ÌýÌýÌý
Emeritus ProfessorÌýProfessor Sir Mark Pepys020 7433 2801
ÌýÌýÌý
Professors/ConsultantsProfessor Philip Hawkins020 7433 2737/2798
ÌýProfessor Ashutosh Wechalekar020 7433 2737/2798
ÌýÌýÌý
Readers/Senior Lecturers/ConsultantsDr Ayesha Shameem Mahmood020 7433 2737/2798
ÌýDr Ana Martinez De Azcona Naharro020 7433 2777
ÌýDr Carol Whelan020 7433 2737/2798
ÌýDr Brendan Wisniowski020 7433 2789
ÌýÌýÌý
Clinical Research StaffDr Rishi Patel020 7433 2777
ÌýDr Sriram Ravichandran020 7433 2763
ÌýDr Yousuf Razvi020 7433 2777
ÌýDr Adam Ioannou020 7433Ìý
ÌýDr Aldostefano Porcari020 7433 2777
ÌýDr Muhammad Umaid Rauf020 7433 2717
ÌýÌýÌý
Lead NurseAngelique Smit020 7433 2770
ÌýÌýÌý
Lead Nuclear Medicine TechnologistDavid Hutt020 7433 2742
ÌýÌýÌý
Service ManagerAyub Hamid020 7794 0500
ÌýÌýÌý
Nursing HelplineÌý020 7433 2799/
07790 989695
ÌýÌýÌý
Specialist/Research NursesDarren FoardÌý
ÌýLisa RanniganÌý
ÌýBellaruth SombritoÌý
ÌýSvetla StrehinaÌý
ÌýMichael WoodÌý
ÌýJoan GalimaÌý
ÌýÌýÌý
ÌýÌýÌý
Clinical Trial CoordinatorSarah LouthÌý
rf-tr.amyloidosisclinicalresearch@nhs.net
020 7433 2723
Interim Service ManagerMichael Walker020 7433 2790
ÌýÌýÌý
Clinical Pathway ManagerRizwan Shaukat020 7433 2732
ÌýÌýÌý
Medical SecretariesCauvery ShelatÌý020 7433 2737/2811
ÌýÌýÌý
Appointmentsrf-tr.amyloidosisappointments@nhs.net020 7433 2812/2725/2800
ÌýÌýÌý
Blood Results (excluding genetic testing results)rf-tr.amyloidosisresults@nhs.net020 7433 2812
ÌýÌýÌý
Transport & AccommodationOnana Ayissi020 7433 2812
ÌýÌýÌý
General Enquiriesrf-tr.amyloidosis-admin@nhs.net020 7433 2811
ÌýÌýÌý
Fax (for academic use only - please do not use for clinical matters)Ìý020 7433 2817


The NHS National Amyloidosis Centre is the only centre in the UK specialising in amyloidosis and is part of University College London Centre for Amyloidosis and Acute Phase Proteins, one of the world's leading centres for amyloid research. The Centre has "state of the art" clinical and research facilities, and a team of highly qualified clinical, research and support staff.

We pioneered scintigraphic imaging (scanning) of amyloid as a quantitative diagnostic procedure and provide a comprehensive clinical service for patients with all types of acquired and hereditary systemic amyloidosis.Ìý The NHS National Amyloidosis Centre is commissioned by NHS National Specialised Services and funded by the Department of Health to provide a diagnostic and management advice service for the UK's national caseload of patients with amyloidosis and related disorders. The clinical service includes:

    • Detailed clinical assessment.
    • Diagnosis, quantification and monitoring of amyloidosis with whole body SAP scintigraphy.
    • Comprehensive expert diagnostic and monitoring studies of the heart, as required, by cardiac magnetic resonance, echocardiography and DPD scanning.
    • Review of diagnostic biopsies and specialised immunohistochemistry to determine amyloid type.
    • Characterisation and exclusion of hereditary amyloidosis by DNA testing; genetic counselling.
    • Measurement and monitoring of specialised biochemical (blood) tests for serum free light chains and serum amyloid A protein.
    • Recommendations for treatment and monitoring response.
    • 3‑12 monthly follow‑up to assess response and further treatment requirements. Sometimes follow‑up assessment can be performed by telephone if patients live far away.
    • Providing information and support to amyloidosis patients, their families and health providers.
    • Systematic evaluation of existing and new treatments.
    • Diagnosis, monitoring and treatment of inherited fever syndromes.